Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 3/20 | 0.63 |
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 0.58 |
| ▸ | MMP2 | P08253 | 6/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23745396 | 0.86 | ADAMTS5 (0.72) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL31121173 | 0.83 | ADAMTS4 (0.70) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL29262510 | 0.81 | ADAMTS5 (0.66) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL23745296 | 0.79 | ADAMTS5 (0.68) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL23745281 | 0.79 | ADAMTS5 (0.62) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL19691587 | 0.77 | ADAMTS4 (1.00) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL23745361 | 0.77 | ADAMTS5 (0.69) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL31121194 | 0.77 | ADAMTS5 (0.69) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL23745413 | 0.77 | ADAMTS5 (0.69) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 | |
| SCHEMBL19691566 | 0.75 | ADAMTS5 (0.81) | ADAMTS4ADAMTS5MMP2MMP13ADAMTS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158626-A1 | ADAMTS INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF | Eternity Bioscience Inc. (US) | 2021-08-12 | — | — | WO | disclosed |